Tokyo, Japan

Kanda Yutaka

This inventor holds 1 USPTO granted patent. Top assignee: Kyowa Hakko Kogyo Kabushiki Kaisha. Active years: 1992.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kanda Yutaka. Retrieved from https://idiyas.com/inventor/kanda-yutaka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 37(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kanda Yutaka: Innovator in Mitomycin Derivatives

Introduction

Kanda Yutaka is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his work on mitomycin derivatives. His innovative approach has led to advancements that may benefit various medical applications.

Latest Patents

Kanda Yutaka holds a patent for mitomycin derivatives. This patent represents his commitment to developing new therapeutic options that can enhance treatment efficacy.

Career Highlights

Yutaka is associated with Kyowa Hakko Kogyo Kabushiki Kaisha, a prominent company in the pharmaceutical industry. His work there has been instrumental in pushing the boundaries of drug development and innovation.

Collaborations

Some of his coworkers include Morimoto Makoto and Ashizawa Tadashi. Their collaborative efforts contribute to the dynamic research environment at Kyowa Hakko Kogyo Kabushiki Kaisha.

Conclusion

Kanda Yutaka's contributions to the field of pharmaceuticals, particularly through his patent on mitomycin derivatives, highlight his role as an innovator. His work continues to inspire advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…